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Mutual inhibitionHyperactivation of NF-κB is a key factor in the pathophysiology of inﬂammatory bowel disease (IBD). We
previously showed that the bile salt nuclear Farnesoid X Receptor (FXR) counter-regulates intestinal
inﬂammation, possibly via repression of NF-κB. Here, we examine whether mutual antagonism between NF-
κB and FXR exists. FXR and its target genes IBABP and FGF15/19 expression were determined in HT29 colon
carcinoma cells and ex vivo in intestinal specimens of wild type (WT) and Fxr-komice, treated with/without
FXR ligands (GW4064/INT-747) and inﬂammatory stimuli (TNFα/IL-1β). In addition, FXR activation was
studied in vivo in WT and Fxr-ko mice with DSS-colitis. The involvement of NF-κB in decreasing FXR activity
was investigated by reporter assays and Glutathione S-transferase pulldown assays. FXR target gene
expression was highly reduced by inﬂammatory stimuli in all model systems, while FXR mRNA expression
was unaffected. In line with these results, reporter assays showed reduced FXR transcriptional activity upon
TNFα/IL-1β stimulation. We show that this reduction in FXR activity is probably mediated by NF-κB, since
overexpression of NF-κB subunits p50 and/or p65 also lead to inhibition of FXR activity. Finally, we report that
p65 and p50 physically interact with FXR in vitro. Conclusions: Together, these results indicate that intestinal
inﬂammation strongly reduces FXR activation, probably via NF-κB-dependent tethering of FXR. Therefore, FXR
not only inhibits inﬂammation, but also is targeted by the inﬂammatory response itself. This could result in a
vicious cycle where reduced FXR activity results in less repression of inﬂammation, contributing to
development of chronic intestinal inﬂammation. This article is part of a Special Issue entitled: Translating
nuclear receptors from health to disease.disease; DSS, dextran sodium
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Inﬂammatory bowel disease (IBD), includingCrohndisease (CD)and
ulcerative colitis (UC), is characterized by chronic intestinal inﬂamma-
tion, with potentially severe complications and even mortality [1].
Although the exact etiology is unclear, it is thought to result from a
combination of dysregulation of the mucosal immune system, hyper-
reactive against the intestinal microbiota, and compromised intestinal
epithelial barrier function in genetically predisposed individuals [2]. In
IBD patients, the nuclear transcription Factor κappa B (NF-κB) was
identiﬁed as a key factor in the pro-inﬂammatory response, resulting in
strongly enhanced expression of pro-inﬂammatory genes and recruit-
ment of excess inﬂammatory cells to the intestinal wall [3]. The NF-κB
complex is a heterodimericproteinpredominantly consistingof p65 and
p50 sub-units [4]. In the absence of activating signals, the inhibitor
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Fig. 2. The pro-inﬂammatory cytokines TNFα and IL-1β inhibit FXR transcriptional
activity. Reporter assays of FXR transcriptional activity on IBABP (A) and SHP
(B) promoter reporter constructs. Cells were transfected with either empty vector
(EV; gray bars) or FXR-RXR (black bars) and treated with DMSO, GW4064 (1 μM), TNFα
(500 U/mL) and IL-1β (20 ng/mL) for 24 h, as indicated. Each bar represents the mean
value±SD; ***pb0.001 compared to GW4064 treated cells.
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cytokines (e.g. TNFα, Il-1β), reactive oxygen species or viral products,
initiates phosphorylation and subsequent degradation of IκBα, allowing
NF-κB to translocate to the nucleus and directly regulate the expression
of speciﬁc target genes [5].
The bile salt nuclear Farnesoid X Receptor (FXR) is a member of the
superfamily of nuclear receptors. Nuclear receptors are ligand-activated
transcription factors that, in response to lipophilic ligands (e.g. hor-
mones, vitamins and dietary lipids), regulate many aspects of mam-
malian physiology, including development, reproduction and
metabolism [6,7]. FXR is mainly expressed in the ileum and liver. Once
activated by bile salts, it regulates transcription of genes involved in bile
salt synthesis, transport andmetabolism [8]. FXR binds as a heterodimer
with Retinoid X Receptor (RXR) to the FXR responsive elements on the
promoters of target genes, such as the small heterodimer partner (SHP),
intestinal bile acid binding protein (IBABP) and ﬁbroblast growth factor
15/19 (FGF15/19 in mouse and human, respectively), involved in bile
salt homeostasis. We have recently found that pharmacological FXR
activation decreases the severity of inﬂammation and preserves the
intestinal barrier integrity in twowell-establishedmurine colitismodels
[9]. In recent years, reciprocal repression between several nuclear
receptors (NR) and inﬂammatory pathways has been described. Acti-
vation of several NRs (e.g. Glucocorticoid Receptor, Androgen Receptor
and Estrogen Receptor) inhibits inﬂammation, whereas activation of
these nuclear receptors is highly reduced in inﬂamed tissues, suggesting
that repression of nuclear receptors might be a mechanism required for
inﬂammation to progress [10]. Also, FXR-mediated gene expressionwas
shown to be suppressed during hepatic inﬂammation [11] and FXR
mRNA expressionwas shown to be reduced in inﬂamed colonicmucosa
in a small cohort of Crohn's patients [12].
In the currentwork,we provide in vitro, ex vivo and in vivo evidence
that the inﬂammatory response reciprocally inhibits activation of FXR
and its target genes in the intestine. These complementary ﬁndings
may have important implications for intestinal inﬂammation and
regulation of bile salt homeostasis in patients with inﬂammatory
bowel disease.
2. Methods
2.1. Cell culture
Human embryonic kidney cells HEK293T and human colon car-
cinoma HT29 (passage number 10–20) cells were grown at 37 °C with
5% CO2 in Dulbecco Modiﬁed Eagle's Medium (DMEM) GlutaMax™
(4.5 g/L D-Glucose and Pyruvate; Gibco BRL, Breda, the Netherlands),
supplemented with 10% heat-inactivated fetal calf serum and 1%
penicillin/streptomycin (Gibco BRL). HT29 cells were maintained
in culture for 7 days in order to allow differentiation into mature
enterocyte-like cells. Both HT29 and HEK293 cells were treated with
DMSO, the synthetic FXR ligand GW4064 (1 uM for 24 h), Tumor
Necrosis Factor α (TNFα; 500 U/mL, for 1, 6 or 24 h, as indicated) or
Interleukin 1β (IL-1β; 20 ng/mL for 24 h). GW4064 is a synthetic FXR
agonist which binds to FXR with an EC 50 of 15 nM [13].
2.2. Reporter assays
HEK293T cellsweregrown in96-multiwell plates and co-transfected
with empty pGL3, pGL3-IBABP or pGL3-SHP reporters, tK-Renilla and
either empty pcDNA or pcDNA-hFXRα2 together with pcDNA-RXRα
using the standard calcium phosphate method, as described elsewhereFig. 1. TNFα decreases Fxr target gene expression in colon carcinoma-derived HT29 cells.
Undifferentiated cells served as control (gray bars). mRNA expression of FXR (A), IBABP (B) a
TNFα (500 U/mL, 1 h, 6 h, 24 h) or both. Each bar represents the mean value±SEM. *pb0.0[14]. After 24 h, cells were incubated with vehicle (DMSO) or 1 μM
GW4064 for 24 h, in presence or absence of either TNFα (500 U/ml) or
IL-1β (20 ng/mL). Alternatively, cells were co-transfected with NF-κB
sub-units pcDNA-p50 and/or pcDNA-p65 (kind gift by Dr. E. Kalkhoven,
Utrecht, The Netherlands). Cells were lysed and Fireﬂy and Renilla
luciferase activity were measured according to manufacturer's in-
structions (Promega Dual-Luciferase Reporter Assay System, Promega,
Madison, Wisconsin, USA) with the Centro LB 960 luminometer
(Berthold Technologies, Vilvoorde, Belgium).2.3. Glutathione S-transferase (GST) pull-down assay
GST-pull downexperimentswereperformedasdescribed elsewhere
[15]. Brieﬂy, p50 and p65 or FXRwere transcribed and translated in vitroHT29 cells were differentiated by culturing them 7 days post-conﬂuency (black bars).
nd FGF19 (C) in HT29 cells incubated with DMSO, the FXR agonist GW4064 (1 μM, 24 h),
5, **pb0.01, ***pb0.001 compared to GW4064 treated cells.
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35
S] methionine and incubated with GST and either
GST-hFXRα2 or GST-p65 fusion proteins, respectively. Samples were
subsequently washed and subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis. Coomassie brilliant blue was used
to visualize GST proteins. [
35
S]-labeled proteins were detected by
autoradiography and analyzed with Storm 820 apparatus (Molecular
dynamics, Pharmacia Biotechnology, Amersham Biosciences, Diegem,
Belgium).
2.4. Animals
Nine-to-twelve weeks oldmale wild type (WT) C57BL/6J micewere
obtained fromCharlesRiver Laboratories. Pure strainmale C57BL/6J Fxr-
komice (Dr. D.J. Mangelsdorf, SouthwesternMedical Center, Dallas, TX)
were kindly provided by Dr. Frank Gonzalez (NIH, Bethesda, MD). Mice
were fed ad libitum and housed in a temperature- and light-controlled
room. All experiments were approved by the Ethical Committee of the
Consorzio Mario Negri Sud and by the Italian Ministry of Health.
2.5. Ex-vivo culturing of murine ileal specimens
Ileal samples of C57Bl/6 wild type (WT; n=4) and Fxr-ko (n=4)
mice were collected, washed with PBS, divided into 6 pieces of
approximately equal size and kept in culture for 24 h at 37 °C with 5%
CO2 inDulbeccoModiﬁed Eagle'sMedium(DMEM)GlutaMax™ (4.5 g/L
D-Glucose and Pyruvate; Gibco BRL, Breda, the Netherlands), supple-
mented with 10% heat-inactivated fetal calf serum and 1% penicillin/
streptomycin (Gibco BRL). The specimens were treated with DMSO,
GW4064 (1 μM) and/or either TNFα (500 U/mL) or IL-1β (20 ng/mL).
After 24 h mRNA was isolated (see below).
2.6. FXR activation and induction of murine colitis
Pharmacological activation of Fxr in mice was accomplished by
daily oral gavage with 5 mg/kg/day INT-747 (6-ethyl-chenodeoxy-
cholic acid, Obeticholic acid, Intercept Pharmaceuticals Inc, New York,
NY) [16] or vehicle (1% wt/vol methyl-cellulose) from 3 days prior to
induction of colitis, and continued until the end of the experiments.
INT 747 is a semi-synthetic FXR ligand activating the receptor with an
EC 50 of approximately 100 nM [16]. Colitis was induced by ad-
ministration of 2.5% (wt/vol) Dextran Sodium Sulfate (DSS; MW 36–
50 kDa, MP Biochemicals Inc., The Netherlands) in drinking water for
10 days (n=8–10 mice per group) [17].
2.7. mRNA extraction and qRT-PCR analysis
Ileal specimens were homogenized (Omni TH tissue homogenizer,
Omni International, Kennesaw, USA) and RNA was isolated using
RNeasy Micro kit (Qiagen GmbH, Hilden, Germany) according to the
manufacturer's instructions. The quantity, quality and integrity of
isolated mRNA were conﬁrmed by absorption measurement and RNA
gel electrophoresis. Subsequently cDNA was generated from 500 ng of
total RNA using SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA) and random hexamers (Roche, Basel, Switzerland).
qRT-PCR analysis was carried out using SYBR green PCR master mix
(Biorad, Veenendaal, The Netherlands) and a MyIQ real time PCR cycler
(Biorad). Values were quantiﬁed using the comparative threshold cycleFig. 3. Overexpression of the NF-κB subunits p50 and p65 inhibits FXR transcriptional activ
reporter constructs transfected with either empty vector (EV; gray bars) or FXR-RXR (bl
***pb0.001 compared to GW4064 treated cells. (C) GST-pull down experiment to analyze p5
experiment with GST-FXR and incubated with either DMSO or GW4064, as indicated. The
brilliant blue staining of GST proteins. (D) GST-pull down experiment to analyze FXR binding
and incubated with either DMSO or GW4064, as indicated. The top panel is a radiograph of [method and FXR and target gene mRNA expression was normalized to
GAPDH. Primers are listed in Supplementary Table 1.
2.8. Statistical analysis
Results are expressed as means±SEM or±SD as indicated in the
ﬁgure legends. ANOVA or Student t test was performed as appropriate
with GraphPad Software (GraphPad Software, Inc., Avenida de la
Playa, La Jolla, USA), as appropriate. Two-sided p-values b0.05 are
considered statistically signiﬁcant and are expressed as *pb0.05;
**pb0.01 and ***pb0.001.
3. Results
3.1. TNFα inhibits FXR target gene expression in differentiated HT29 cells
To study the effects of an inﬂammatory stimulus on FXR target
gene expression, we treated undifferentiated and differentiated HT29
colon carcinoma cells with TNFα in the presence or absence of the FXR
synthetic ligand GW4064. In undifferentiated enterocytes, none of the
treatments exerted any effects on FXR, IBABP or SHP expression. FXR
is expressed and functional exclusively in fully differentiated HT29
cells (Fig. 1A), in line with its in vivo intestinal expression, which is
limited to the villi of the enterocyte [18]. There was no signiﬁcant
difference in FXRmRNA expression between the various experimental
conditions in differentiated cells (Fig. 1A). GW4064markedly induced
the FXR target genes IBABP and FGF19, only in differentiated cells
(Fig. 1B and C). Co-treatment with TNFα dramatically reduced IBABP
and FGF19 expression in a time-dependent manner, indicating that in
the presence of a pro-inﬂammatory stimulus, FXR activation is
inhibited (Fig. 1B and C). TNFα treatment alone did not affect IBABP
and FGF19 mRNA expression (Fig. 1B and C).
3.2. The pro-inﬂammatory cytokines TNFα and IL-1β inhibit FXR
transcriptional activity
In order to investigate whether pro-inﬂammatory agents (TNFα
and IL-1β) decrease FXR target gene expression by inhibiting FXR
transcriptional activity, HEK293 cells were transiently transfected
with IBABP or SHP reporter constructs alone or in combination with
FXR and RXR expression plasmids, and incubated with GW4064 and
either TNFα or IL-1β. FXR transcriptional activity of IBABP and SHP
promoters was markedly increased by GW4064, while neither TNFα
nor IL-1β had any effect on basal luciferase expression. Strikingly,
TNFα or IL-1β in combination with GW4064 markedly decreased the
IBABP- and SHP-responsive luciferase expression compared to
GW4064 alone (Fig. 2A and B), suggesting that the inhibition of FXR
target gene expression by these pro-inﬂammatory cytokines is due to
a decrease in FXR transcriptional activity.
3.3. Overexpression of the NF-κB subunits p50 and p65 inhibits FXR
transcriptional activity
Since TNFα and IL-1β activate NF-κB, we next explored whether
NF-κB subunits (p50 and p65) directly affect FXR transcriptional
activity. HEK293 cells were transfected with either pGL3-IBABP or
pGL3-SHP promoter reporter constructs together with FXR and RXR inity. Reporter assays of FXR transcriptional activity on IBABP (A) and SHP (B) promoter
ack bars) together with p50, p65 or both. Each bar represents the mean value±SD;
0 and p65 binding to FXR. In vitro translated p50 and p65 were subjected to a pull-down
top panel is a radiograph of [
35
S]-labeled p50 and p65; the lower panel is a Coomassie
to p65. In vitro translated FXR was subjected to a pull-down experiment with GST-p65
35S]-labeled FXR; the lower panel is a Coomassie brilliant blue staining of GST proteins.
Fig. 4. TNFα and IL-1β decrease Fxr target gene expression in ex-vivo cultured mouse
ileal mucosa. Ileal specimens were prepared fromWT and Fxr-komice, cultured ex vivo
and treated for 24 h with DMSO, GW4064, TNFα and IL-1β, as indicated. mRNA
expression of Fxr (A) and Fxr target genes Ibabp (B) and Fgf15 (C) in the ileal mucosa of
WT (black bars) and Fxr-komice (gray bars). Each bar represents themean value±SEM.
*pb0.05 compared to GW4064-treated mice.
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GW4064-dependent IBABP and SHP promoter activity (by 42% and
85%, respectively) and p65 decreased GW4064-dependent IBABP and
SHP promoter activities by 97% and 98%, respectively. Co-transfection
of p50 and p65 completely abolished GW4064-dependent IBABP and
SHP promoter activity (Fig. 3A and B). These results suggest that the
inhibition of FXR transcriptional activity is mediated by NF-κB.
3.4. FXR interacts with the NF-κB subunits p50 and p65 in a GST-pull
down assay
To investigate whether the decrease of FXR transcriptional activity
is due to physical interaction between FXR and the NF-κB subunits
p50 and p65, a GST-pull down assay was performed. The NF-κB
subunits p65 and p50 bind to FXR, in a ligand independent fashion
(Fig. 3C). Also, GST-pull down assays performed with GST-p65 fusion
proteins and [
35
S]-labeled FXR, revealed interaction between FXR and
the NF-κB subunit p65 (Fig. 3D).
3.5. Fxr activation is inhibited by TNFα and IL-1β in ex-vivo ileal samples
of WT and Fxr-ko mice
To extrapolate our in vitro ﬁndings, we prepared ileal specimens
from WT and Fxr-ko mice, and cultured them ex vivo in the presence
or absence of GW4064 and either TNFα or IL-1β. Fxr expression in the
ileal specimens did not change under any of the described conditions
(Fig. 4A). TNFα and IL-1β treatment alone did not affect Fxr target
gene mRNA expression. GW4064 induced the Fxr target genes Ibabp
and Fgf15, only in WT mice. TNFα or IL-1β treatment in combination
with GW4064 dramatically reduced Ibabp and Fgf15 expression com-
pared to GW4064 treatment alone (Fig. 4B and C), indicating that Fxr
activity is reduced.
3.6. Fxr activation is decreased in the ileum and colon of mice with
DSS-induced colitis
To explore the inhibition of Fxr activity by inﬂammatory stimuli in
vivo, we investigated whether DSS-induced inﬂammation inhibits
Fxr-dependent gene expression in the ileal and colonic mucosa of WT
and Fxr-ko mice. Fxr was expressed in WT mice, but not Fxr-ko mice.
FxrmRNA expression was not affected by DSS and/or INT747 (Fig. 5A
and C). Nevertheless, INT-747 activated ShpmRNA expression in WT,
but not in Fxr-ko mice. Concomitant induction of colitis by DSS
markedly reduced Shp mRNA expression induced by INT-747 in the
ileum (Fig. 5B). A similar trend was observed in the colon (Fig. 5D).
4. Discussion
We have recently found that FXR is an important player in the
counter-regulation of intestinal inﬂammation. In particular, the potent
semi-synthetic FXR agonist INT-747 improves clinical symptoms and
histology in the DSS and TNBSmurinemodels of colitis. These beneﬁcial
effects are only detected in WT mice, not in Fxr-ko mice. Also, Fxr
activation inhibits the increase of epithelial permeability and pro-
inﬂammatory cytokine mRNA expression in the murine intestinal
mucosa, under these circumstances [9]. The multi-level protection
against intestinal inﬂammation provides a clear rationale to further
explore FXR agonists as a novel therapeutic strategy for IBD. Current
treatment options for IBD are mainly aimed at suppressing the immune
response. Although reasonably effective, signiﬁcant side effects and
treatment failures can occur, stressing the need for novel treatment
options for IBD. Therefore, a therapeutic trial with currently available
FXR agonists in patients with inﬂammatory bowel disease seems
warranted, in analogy of currently performed trials with INT-747 in
patients with the cholestatic liver disease primary biliary cirrhosis [19].In the present study, we show mutual crosstalk between FXR and
proinﬂammatory stimuli, because not only does FXR inhibit inﬂamma-
tion, but also FXR activation is inhibited by pro-inﬂammatory stimuli in
different model systems. Firstly, the pro-inﬂammatory cytokine TNFα
decreases FXR target gene expression in enterocyte-like differentiated
HT29 cells. Thisﬁndingwas conﬁrmed in ileal specimens ofWT and Fxr-
komice cultured ex vivo, in which we also showed decreased Fxr target
Fig. 5. DSS-induced colitis decreases Fxr activation in WTmice. DSS colitis was induced inWT and Fxr-komice pre-treated with or without INT-747. mRNA expression of Fxr and Shp
in the ileal (A, B) and colonic mucosa (C, D) of WT (black bars) and Fxr-komice (gray bars). Each bar represents the mean value±SEM. **pb0.01, ***pb0.001 compared to WT INT-
747-treated mice.
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with severe intestinal inﬂammation induced by DSS, expression of Fxr
target genes Ibabp and Fgf15was similarly reduced in ileum aswell as in
colon. Although DSS administration leads primarily to colitis, effects on
FXR target gene expression in the ileum of DSS-treated mice may be
explained by increased levels of circulating pro-inﬂammatory cytokines
originating from the colonic lesions. In line with the data shown in this
paper, we have preliminary data indicating that ileal expression of the
FXR target gene SHP is markedly lower (50%) in patients with Crohn
colitis in clinical remission (unpublished data). In Crohn's patients and
the in vitro and ex vivomodels presented in this paper FXR expression
itself is not signiﬁcantly changed by pro-inﬂammatory cytokines,
indicating that the inhibition of FXR target gene expression is due to
decreased FXR activity.
Based on these results, it can be anticipated that ablation of Fxr
would lead to more severe intestinal inﬂammation. Indeed, we
observed that Fxr-ko mice have severely impaired intestinal integrity
compared to WT mice at baseline (Supplementary Figure 3 of [9]),
suggesting that they are probably more susceptible to chronic
inﬂammation. However, we did not ﬁnd more severe colitis in Fxr-
komice than inwild typemice treatedwith DSS. Thismay relate to the
short duration of the DSS protocol, the young age of the mice and/or
the micro-environmental conditions. It is also possible that the severe
inﬂammation in the DSS model does not allow detecting subtle
differences between Fxr-ko and wild type mice.
This study shows that FXR is not only an active player in the
inhibition of inﬂammation, but also is a target of the inﬂammatoryresponse itself. This could result in a vicious cycle where reduced FXR
activity results in less repression of intestinal inﬂammation, contrib-
uting to development of chronic intestinal inﬂammation. Together,
these ﬁndings imply an important role for FXR in the protection
against IBD.We also hypothesize that decreased FXR activity may lead
to altered bile salt enterohepatic circulation and potentially relate to
cholestatic liver disease, which often coexists in patients with in-
ﬂammatory bowel disease [20].
In recent years, a reciprocal regulation between several steroid NRs
on the one hand and inﬂammatory pathways on the other hand has
been described. Little is known about the exact mechanisms underlying
these processes. For example, NF-κB has been shown to suppress PXR
regulated gene expression, by interferingwith the binding of PXR to the
PXR responsive element [21]. In the current study, we also show direct
involvementofNF-κB in repression of FXR activity, since overexpression
ofNF-κB subunits p50andp65 inhibits FXR activity andhas the ability to
physically interact with FXR. Similarly to PXR, NF-κB may inhibit FXR
activation by preventing binding of FXR to its cognate FXR responsive
element in the DNA. However, at this stage, we cannot rule out other
potential mechanisms such as the competition between the nuclear
receptor and the NF-κB complex for a common transcriptional cofactor
(“cofactor squelching”).
It has long been appreciated that inﬂammation affects bile homeo-
stasis and that bile salts have immune suppressive actions. Although
additional mechanisms may exist, our work provides insights in the
mechanisms by which bile salts interact with the immune system via
FXR.
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In this paper we show that in addition to the role of FXR in counter-
regulation of the intestinal inﬂammatory response, [9] there is re-
ciprocal inhibition of the FXR pathway by the inﬂammatory response.
We provide evidence for the involvement of NF-κB in this suppressive
effect. The crosstalk between NF-κB and FXR at the intestinal level
indicates an interaction between lipid metabolism and inﬂammatory
disease and leads to new insights in pathogenesis and potentially also to
novel treatment strategies for inﬂammatory bowel disease.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.04.005.
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